Dr. Michael Poiesz
Claim this profileWoodlands Medical Specialists
Studies Colorectal Cancer
Studies Breast Cancer
3 reported clinical trials
14 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
HER2 positive
Stage III
2Breast Cancer
Stage I
Stage II
HER2 negative
Affiliated Hospitals
Clinical Trials Michael Poiesz is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Lutetium (177Lu) Vipivotide Tetraxetan
for Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Recruiting2 awards Phase 36 criteria
More about Michael Poiesz
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michael Poiesz has experience with
- Oxaliplatin
- Bevacizumab
- Levoleucovorin
- Tucatinib
- Trastuzumab
- Fluorouracil
Breakdown of trials Michael Poiesz has run
Colorectal Cancer
Breast Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Poiesz specialize in?
Michael Poiesz focuses on Colorectal Cancer and Breast Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Michael Poiesz currently recruiting for clinical trials?
Yes, Michael Poiesz is currently recruiting for 3 clinical trials in Pensacola Florida. If you're interested in participating, you should apply.
Are there any treatments that Michael Poiesz has studied deeply?
Yes, Michael Poiesz has studied treatments such as Oxaliplatin, Bevacizumab, Levoleucovorin.
What is the best way to schedule an appointment with Michael Poiesz?
Apply for one of the trials that Michael Poiesz is conducting.
What is the office address of Michael Poiesz?
The office of Michael Poiesz is located at: Woodlands Medical Specialists, Pensacola, Florida 32503 United States. This is the address for their practice at the Woodlands Medical Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.